---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095801"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:41:12.039303+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q2 2024 revenue flat at $4.0M; gross margin improves to 47%, adjusted EBITDA near breakeven

## Summary
- Revenue $4.0M flat YoY and sequentially; B2C sales up 4% offset by B2B decline of 3%.
- Gross margin 47.0% vs 43.3% YoY, best in 13 quarters; operating loss narrowed to $0.6M from $1.1M.
- Adjusted EBITDA loss just $6,000, near cash-flow breakeven; cash balance $0.5M vs $1.3M year-end 2023.
- Closed acquisition of Elevated Softgels in May 2024; appointed Maxim Group as financial advisor for strategic options.
- Received net proceeds of $0.9M from Streeterville financing; remains top hemp extract brand per SPINS.

## SEC filing metadata
- accession: 0000950170-24-095801
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000095017024095801/0000950170-24-095801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000095017024095801/cvsi-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095801
- JSON: https://secwatch.observer/filing/0000950170-24-095801.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.